Investigators at Tulane University Report Findings in Personalized Medicine (Prediction of Resistance To <superscript>177</superscript>lu-psma Therapy By Assessment of Baseline Circulating Tumor Dna Biomarkers).
In: Drug Week, 2024-01-30, S. 748-748
serialPeriodical
Zugriff:
A recent study conducted at Tulane University in New Orleans, Louisiana, explored the use of biomarkers to predict resistance to 177Lu-PSMA therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). The study collected pretreatment circulating tumor DNA (ctDNA) samples from 44 mCRPC patients receiving 177Lu-PSMA treatment. The findings indicated that nonresponders were more likely to have gene amplifications, particularly in FGFR1 and CCNE1, and CDK12 mutations were more likely to be present in nonresponders. However, further studies are needed to confirm these findings before they can be used to guide personalized treatment decisions. [Extracted from the article]
Copyright of Drug Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Investigators at Tulane University Report Findings in Personalized Medicine (Prediction of Resistance To <superscript>177</superscript>lu-psma Therapy By Assessment of Baseline Circulating Tumor Dna Biomarkers).
|
---|---|
Zeitschrift: | Drug Week, 2024-01-30, S. 748-748 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 1531-6440 (print) |
Sonstiges: |
|